These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 15372102)
1. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102 [TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126 [TBL] [Abstract][Full Text] [Related]
4. Role of prostacyclin in the cardiovascular response to thromboxane A2. Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481 [TBL] [Abstract][Full Text] [Related]
5. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791 [TBL] [Abstract][Full Text] [Related]
6. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809 [TBL] [Abstract][Full Text] [Related]
7. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. McClelland S; Gawaz M; Kennerknecht E; Konrad CS; Sauer S; Schuerzinger K; Massberg S; Fitzgerald DJ; Belton O Atherosclerosis; 2009 Jan; 202(1):84-91. PubMed ID: 18514659 [TBL] [Abstract][Full Text] [Related]
8. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Foteinos G; Hu Y; Xiao Q; Metzler B; Xu Q Circulation; 2008 Apr; 117(14):1856-63. PubMed ID: 18378610 [TBL] [Abstract][Full Text] [Related]
9. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Tarín C; Gomez M; Calvo E; López JA; Zaragoza C Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):27-32. PubMed ID: 18988893 [TBL] [Abstract][Full Text] [Related]
10. [Terutroban and endothelial TP receptors in atherogenesis]. Verbeuren TJ Med Sci (Paris); 2006 Apr; 22(4):437-43. PubMed ID: 16597416 [TBL] [Abstract][Full Text] [Related]
11. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605 [TBL] [Abstract][Full Text] [Related]
12. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034 [TBL] [Abstract][Full Text] [Related]
13. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Davenport P; Tipping PG Am J Pathol; 2003 Sep; 163(3):1117-25. PubMed ID: 12937153 [TBL] [Abstract][Full Text] [Related]
14. Circulating adhesion molecules in apoE-deficient mouse strains with different atherosclerosis susceptibility. Tian J; Pei H; James JC; Li Y; Matsumoto AH; Helm GA; Shi W Biochem Biophys Res Commun; 2005 Apr; 329(3):1102-7. PubMed ID: 15752767 [TBL] [Abstract][Full Text] [Related]
15. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis. Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803 [TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Babaev VR; Ding L; Reese J; Morrow JD; Breyer MD; Dey SK; Fazio S; Linton MF Circulation; 2006 Jan; 113(1):108-17. PubMed ID: 16380543 [TBL] [Abstract][Full Text] [Related]
17. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Schulz C; Konrad I; Sauer S; Orschiedt L; Koellnberger M; Lorenz R; Walter U; Massberg S Thromb Haemost; 2008 Jan; 99(1):190-5. PubMed ID: 18217153 [TBL] [Abstract][Full Text] [Related]